← Browse by Condition

Medical Condition

non small cell lung cancer

Total Trials

75

Recruiting Now

75

Trial Phases

Phase 2, Phase 3, Phase 1

SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer

The First People's Hospital of...

BostonGene and Exigent Genomic INsight Study

Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)

Detection of Circulating Tumour Cells, Spread Through Air Space in Patients With Lung Cancer

IRCCS Azienda Ospedaliero-Univ...

NCT06755684 Phase 2

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

NCT05922345 Phase 3

Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.

Chia Tai Tianqing Pharmaceutic...

NCT05657873 Phase 2

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

Memorial Sloan Kettering Cance...

NCT05334277 Phase 2

Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

Sun Yat-sen University

NCT05104788 Phase 2

A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Peking University Cancer Hospi...

NCT06268210 Phase 2

Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer

Yonsei University

NCT05014464 Phase 2

ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma

Hunan Province Tumor Hospital

NCT06969027 Phase 2

JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC

Shanghai Junshi Bioscience Co....

NCT05452005 Phase 1

Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer

University of California, Davi...

Dietary Intervention for NSCLC Patients Treated With ICI

Centre hospitalier de l'Univer...

NCT06047379 Phase 1, Phase 2

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

NCT06123754 Phase 3

Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC

3D Medicines (Sichuan) Co., Lt...

NCT06896422 Phase 1

Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC

The First Affiliated Hospital ...

NCT05076760 Phase 1

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

NCT05654454 Phase 3

A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

National Cancer Institute (NCI...

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

Henan Cancer Hospital

NCT07216105 Phase 1

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Fate Therapeutics

NCT06486142 Phase 3

EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

NCT06706713 Phase 2

Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer

BeBetter Med Inc

NCT06275360 Phase 2

Repositioning Immunotherapy in VetArans With Lung Cancer

VA Office of Research and Deve...

NCT04322578 Phase 2

Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC

Hunan Province Tumor Hospital

NCT06718309 Phase 2

Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC

First People's Hospital of Han...

NCT06902272 Phase 2

ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer

University of Miami

NCT06789172 Phase 1

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

United States, Austr...

NCT07261631 Phase 1

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

Canada, France, Isra...

Novartis Pharmaceuticals

NCT06124118 Phase 1

Tumor Treating Fields for Locally Advanced NSCLC

University of Utah

NCT06711900 Phase 3

A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Sichuan Kelun-Biotech Biopharm...

NCT05522660 Phase 3

Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer

Italy, Netherlands, ...

ETOP IBCSG Partners Foundation

NCT06731907 Phase 2

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

United States, Chile...

Merck Sharp & Dohme LLC

NCT06394674 Phase 2

High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib

Changhai Hospital

Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors

Goethe University

Hybrid Prehabilitation Before Thoracic Surgery

ADIR Association

LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)

University of California, Davi...

NCT06311981 Phase 2

Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients

NCT06448754 Phase 2

Volrustomig Priming Regimens Exploratory Phase II Platform Study

United States, Canad...

Osimertinib for Advanced EGFR-positive NSCLC Patients

National University Hospital, ...

CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC

NCT07195695 Phase 3

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

United States, Argen...

Boehringer Ingelheim

NCT05241028 Phase 2

Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer

Hebei Medical University Fourt...

NCT04282044 Phase 1

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

BioEclipse Therapeutics

NCT07249372 Phase 2

DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer

NYU Langone Health

NCT07202364 Phase 2

A Study of YL202 in Patients With Advanced Solid Tumors

MediLink Therapeutics (Suzhou)...

NCT05519293 Phase 1, Phase 2

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

Copenhagen Master Observational Trial

Rigshospitalet, Denmark

Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery

Liaoning Cancer Hospital & Ins...

POINTING: Clinical Cohort Study of Patients With Melanoma and NSCLC Receiving Checkpoint Inhibitors

University Medical Center Gron...

Multimodal Prehabilitation in Patients with Lung Cancer Undergoing Neoadjuvant Therapy

Hospital Clinic of Barcelona

NCT04585477 Phase 2

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

Stanford University

NCT03476681 Phase 1, Phase 2

Study of NEO-201 in Solid Tumors Expansion Cohorts

Precision Biologics, Inc

NCT06646471 Phase 4

PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies

GFPC Investigation

NCT07014202 Phase 2

Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy

Cancer Institute and Hospital,...

NCT06810544 Phase 1, Phase 2

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Tango Therapeutics, Inc.

NCT06765109 Phase 3

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

United States, Argen...

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

NCT06702826 Phase 2

Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases

NCT06043817 Phase 1, Phase 2

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

United States, Franc...

Pierre Fabre Medicament

NCT05800340 Phase 2

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Guangdong Provincial People's ...

NCT06586515 Phase 1

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

United States, Canad...

Eli Lilly and Company

NCT04585750 Phase 1, Phase 2

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

United States, Austr...

PMV Pharmaceuticals, Inc

NCT05751018 Phase 2

Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer

Peking Union Medical College H...

GT201 Injection in Combination with Teraplizumab Injection for Treatment of Patients with Non-small Cell Lung Cancer

Grit Biotechnology

NCT07182682 Phase 3

A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery

Dizal (Jiangsu) Pharmaceutical...

NCT07183189 Phase 3

A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

Suzhou Suncadia Biopharmaceuti...

NCT06281678 Phase 2

A Study of IBI363 in Subjects with Advanced Solid Malignancies

Innovent Biologics (Suzhou) Co...

NCT04401059 Phase 4

Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study

Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.

Origin Sciences

NCT05627960 Phase 1

First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

A&G Pharmaceutical Inc.

NCT07174908 Phase 3

A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

InxMed (Shanghai) Co., Ltd.

NCT07362940 Phase 1, Phase 2

A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib

Henan Genuine Biotech Co., Ltd...

NCT04322890 Phase 2

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Hunan Province Tumor Hospital